Should the schedule of disease modifying therapy medication administration be changed if patient has received high dose steroids for an MS exacerbation?

This is an interesting question. I usually do not withhold or change the schedule of disease-modifying therapy while treating acute relapses with high-dose steroids. This overlap may be a concern for agents such as anti-CD20 monoclonal antibodies in which induced inflammation and subsequent cell death could be modulated by high-dose steroids. However, I have not seen data in multiple sclerosis or other autoimmune conditions (such as vasculitis) to support the impaired effect of the DMT with high...